Sorafenib, a multikinase inhibitor with antiangiogenic activity, is an approved therapy for
hepatocellular carcinoma (HCC). It is unclear whether the proinflammatory and …

Tumor-associated macrophages, crucial components of the microenvironment in
hepatocellular carcinoma, hamper anti-cancer immune responses. The aim of the present …

Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the standard of care for
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …

Novel promising strategies for combination with sorafenib are urgently needed to enhance
its clinical benefit and overcome toxicity in hepatocellular carcinoma (HCC). the molecular …

Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …

Surgical resection is the first‐line treatment for hepatocellular carcinoma (HCC) patients with
well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is …

Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced
hepatocellular carcinoma (HCC). The present study was undertaken to determine whether …

Alternatively polarized macrophages (Mϕ) shape the microenvironment of hepatocellular
carcinoma (HCC) and temper anticancer immune responses. We investigated if sorafenib …

Background Sorafenib is the most widely used first-line treatment for patients with advanced
hepatocellular carcinoma (HCC), but such treatment provides only limited survival benefits …

Antiangiogenic and cytotoxic effects are considered the principal mechanisms of action of
sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular …